15-6-11　ⓔ文献

  1. Bilimoria KY, Shen WT, et al: Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors. Cancer, 2008; 113: 3130–3136.

  2. Ng L, Libertino JM: Adrenocortical carcinoma: diagnosis, evaluation and treatment. J Urol, 2003; 169: 5.

  3. Allolio B, Fassnacht M: Clinical review: Adrenocortical carcinoma: clinical update. J Clin Endocrinol Metab, 2006; 91: 2027.

  4. Fassnacht M, Johanssen S, et al: Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification. Cancer, 2009; 115: 243.

  5. Koch CA, Pacak K, et al: The molecular pathogenesis of hereditary and sporadic adrenocortical and adrenomedullary tumors. J Clin Endocrinol Metab, 2002; 87: 5367.

  6. Sandrini R, Ribeiro RC, et al: Childhood adrenocortical tumors. J Clin Endocrinol Metab, 1997; 82: 2027.

  7. Pinto EM, Chen X, et al: Genomic landscape of paediatric adrenocortical tumours. Nat Commun, 2015; 6: 6302.

  8. Weiss LM, Medeiros LJ, et al: Pathologic features of prognostic significance in adrenocortical carcinoma. Am J Surg Pathol, 1989; 13: 202.

  9. Aubert S, Wacrenier A, et al: Weiss system revisited: a clinicopathologic and immunohistochemical study of 49 adrenocortical tumors. Am J Surg Pathol, 2002; 26: 1612.

  10. Lau SK, Weiss LM: The Weiss system for evaluating adrenocortical neoplasms: 25 years later. Hum Pathol, 2009; 40: 757.

  11. Melmed S, Polonsky KS, et al: Williams Textbook of Endocrinology. 12th ed, Saunders, 2011.

  12. Arlt W, Biehl M, et al: Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors. J Clin Endocrinol Metab, 2011; 96: 3775.

  13. Angeli A, Osella G, et al: Adrenal incidentaloma: an overview of clinical and epidemiological data from the National Italian Study Group. Horm Res, 1997; 47: 279.

  14. Icard P, Goudet P, et al: Adrenocortical carcinomas: surgical trends and results of a 253–patient series from the French Association of Endocrine Surgeons study group. World J Surg, 2001; 25: 891.

  15. Hermsen IG, Fassnacht M, et al: Plasma concentrations of o,p'DDD, o,p'DDA, and o,p'DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study. J Clin Endocrinol Metab, 2011; 96: 1844.

  16. Fassnacht M, Terzolo M, et al: Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med, 2012; 366: 2189–2197.

  17. Carneiro BA, Konda B, et al: Nivolumab in Metastatic Adrenocortical Carcinoma: Results of a Phase 2 Trial. J Clin Endocrinol Metab, 2019; 104: 6193–6200.

  18. Terzolo M, Angeli A, et al: Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med, 2007; 356: 2372–2380.

  19. Giordano TJ: The argument for mitotic rate–based grading for the prognostication of adrenocortical carcinoma. Am J Surg Pathol, 2011; 35: 471.

  20. Fassnacht M, Dekkers OM, et al: European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol, 2018; 179: G1–G46.

  21. Fassnacht M, Hahner S, et al: Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma. J Clin Endocrinol Metab, 2006; 91: 4501–4504.

  22. Gharzai LA, Green MD, et al: Adjuvant radiation improves recurrence-free survival and overall survival in adrenocortical carcinoma. J Clin Endocrinol Metab, 2019; 104: 3743–3750.